REFRACTORY WHO GRADE 2 GLIOMA
Clinical trials for REFRACTORY WHO GRADE 2 GLIOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY WHO GRADE 2 GLIOMA trials appear
Sign up with your email to follow new studies for REFRACTORY WHO GRADE 2 GLIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Precision drug ivosidenib tested in kids with tough IDH1 cancers
Disease control OngoingThis study tests a drug called ivosidenib in children and young adults (ages 1-21) whose cancers have a specific IDH1 gene change and have either returned or not responded to standard treatments. The goal is to see if the drug can shrink tumors. Only 3 participants were enrolled,…
Matched conditions: REFRACTORY WHO GRADE 2 GLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 05:07 UTC
-
New hope for kids with rare cancers: targeted drug takes aim at HRAS gene
Disease control OngoingThis study tests a drug called tipifarnib in children and young adults (ages 1 to 21) whose cancer has returned or spread and has a specific change in the HRAS gene. The goal is to see if the drug can shrink tumors or stop them from growing. About 5 participants received the drug…
Matched conditions: REFRACTORY WHO GRADE 2 GLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 05:05 UTC
-
New targeted drug shows promise for kids with rare RET-Driven cancers
Disease control OngoingThis study tests a drug called selpercatinib in children and young adults (ages 1 to 21) whose cancers have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. The trial is for patients with advanced solid…
Matched conditions: REFRACTORY WHO GRADE 2 GLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:57 UTC